BioVersys Commences Key Phase 3 Trial for BV100

BioVersys AG has announced the initiation of its pivotal Phase 3 RIV-TARGET trial for BV100, a novel anti-infective agent targeting hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) due to carbapenem-resistant Acinetobacter baumannii (CRAB). This trial, registered under NCT07326540, marks a significant milestone in evaluating BV100, which is anticipated to provide a new therapeutic option for critically ill patients.

The study aims to enroll about 300 patients across 100 sites in approximately 15 countries, comparing BV100 plus low-dose polymyxin B with colistin plus high-dose ampicillin-sulbactam. A prior Phase 2 trial demonstrated a 50% reduction in mortality with BV100, emphasizing its potential efficacy.

Recognized for its high drug resistance, CRAB presents a critical challenge in global healthcare. BV100, which has received the U.S. FDA's Qualified Infectious Disease Product designation, is expected to complete patient enrollment by the end of 2027, with regulatory submissions planned for 2028.